Research Article

CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome

Table 2

Concentration and functional activity of complement proteins in patients with thrombotic APS and healthy controls.

ParameterPatientsaPL positive controlsSLE controlsHealthy controlsP
( ) ( )( )( )

C3, mean ± SD
mg/dL (range)
97.7 ± 26.3
(58–156)
108.8 ± 39
(61–202)
77 ± 20
(27–106)
113.4 ± 40.6
(61–305)
0.35a, 0.05b, 0.04c
Low C3 (%)141.230.843.819.20.74a, 0.76b, 0.04c
C4, mean ± SD
mg/dL (range)
16.9 ± 8.5
(2–41)
21 ± 7
(12–35)
15 ± 6
(5–27)
23.9 ± 9.6
(12.8–74.4)
0.19a, 0.58b, 0.001c
Low C4 (%)263.938.556.317.30.14a, 0.77b, <0.01c
FB, mean ± SD
mg/dL (range)
33 ± 7.7
(14–46.1)
31 ± 8
(21.9–47.1)
28 ± 6
(23–34)
31.0 ± 8.27
(20–63)
0.83a, 0.45b, 0.28c
Low FB (%)33.330000.54a, 0.83b, 0.37c
CH100, mean ± SD
Units/mL (range)
46.9 ± 17.9
(20–70)
60 ± 27
(23–89)
63 ± 24
(36–102)
70.5 ± 31.5
(20–165)
0.19a, 0.23b, 0.01c
Low CH100 (%)464.357.171.459.40.37a, 0.63b, 0.51c

APS: antiphospholipid syndrome; aPL positive controls: aPL+ patients without APS clinical criteria; HC: healthy controls; FB: factor B; 1C3 normal range: 83–172 mg/dL; 2C4 normal range: 17–51 mg/dL; 3FB normal range: 19–50 mg/dL; 4CH100 normal range: >70 units/mL. aANOVA comparison of thrombotic APS with aPL+ controls, bANOVA comparison of thrombotic APS with SLE controls, and cANOVA comparison of thrombotic APS with healthy controls.